Search | Clinical Trials Finder

Conditions: Infant Safe Sleep Practices, SIDS
Interventions: Safe Sleep Education, Behavior habit tracking; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: Up to 3 Months
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Sexual Violence, Posttraumatic Stress Disorder (PTSD), Opioid Misuse
Interventions: Skills Training in Active Recovery (STAR) Video, Text Skills Training in Active Recovery (TextSTAR) program; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Louisville, Kentucky • Chapel Hill, North Carolina • Madison, Wisconsin

Conditions: Traumatic Brain Injury
Interventions: Minocycline; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Dearborn, Michigan • Trenton, Michigan

Conditions: Septic Shock
Interventions: Seraph-100 + State of the Art Care, State of the Art Care; Device
Lead sponsor: ExThera Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more

Conditions: Resistance Training, Colon Cancer, Chemotherapy Effect
Interventions: Resistance training; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 3
States / cities: Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Emerfetamab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Birmingham, Alabama • Duarte, California • Houston, Texas + 1 more

Conditions: Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions: 5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Suicidal and Self-injurious Behavior
Interventions: Safety Study Lethal Means Counseling; Behavioral
Lead sponsor: Northeastern University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 575 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Colorado Springs, Colorado • Fort Collins, Colorado • Loveland, Colorado + 2 more

Conditions: Sexual Violence
Interventions: Green Dot, Wellness Initiatives for Student Empowerment; Behavioral
Lead sponsor: University of Kentucky; Other
Eligibility: 18 Years to 24 Years
Enrollment: 427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Cardiovascular Disease, Hyperlipidemia
Interventions: Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin; Drug · Diagnostic Test
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prescription Drug Abuse
Interventions: MyHealthyChoices, Health Risk Assessment; Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Morgantown, West Virginia

Conditions: Hodgkin Lymphoma
Interventions: doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 9
States / cities: Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more

Conditions: Drive, Adolescent Behavior, Risk Behavior
Interventions: Steering Teens Safe (STS), Driving Feedback Technology.; Behavioral
Lead sponsor: Ginger Yang; Other
Eligibility: 16 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Diabetes Complications, Diabetic Nephropathies, Autoimmune Diabetes
Interventions: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF), Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR); Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Conditions: Prodromal Alzheimer's Disease
Interventions: Partnered Rhythmic Rehabilitation (PRR), Group walking (WALK); Other
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Shaken Baby Syndrome, Crying, Trauma
Interventions: The Purple Cry Intervention, Control Intervention; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Meibomian Gland Dysfunction, Dry Eye
Interventions: Lipiflow Thermal Pulsation System, iLux System; Device
Lead sponsor: Epstein, Arthur B., OD, FAAO; Individual
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Sepsis, Critical Illness, ICU-acquired Muscle Weakness, ICU-acquired Weakness, ICUAW, Sarcopenia, Secondary Sarcopenia
Interventions: Electrical Muscle Stimulation System; Device
Lead sponsor: Health Discovery Labs; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Rochester, Minnesota • Austin, Texas

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Rituximab, Fludarabine, Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells; Drug · Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Thoracic Surgery, Thoracic Trauma
Interventions: Not listed
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct
Interventions: oxaliplatin, capecitabine, Keytruda, CDX-1140; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2042
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: ExPEC4V (4 : 4 : 4 : 4), ExPEC4V (4 : 4 : 4 : 8), ExPEC4V (8 : 8 : 8 : 8), ExPEC4V (8 : 8 : 8 : 16), ExPEC4V (16 : 16 : 16 : 16), Placebo; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 848 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 17
States / cities: Mesa, Arizona • Hollywood, Florida • Leesburg, Florida + 14 more

Conditions: Oral Health
Interventions: PTx800 lozenges, Placebo control; Dietary Supplement
Lead sponsor: Primal Therapies Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Infant Safe Sleep in Pediatric Emergency Depratment

Testing STAR and TextSTAR: A Randomized Controlled Trial

Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)

Blood Purification for the Treatment of Pathogen Associated Shock

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

An ED-based RCT of Lethal Means Counseling for Parents of At-Risk Youth

A Pilot of Bystander Training Programming in Sexual Violence and Subtance Abuse

Effect of Evolocumab on Coronary Atherosclerosis

Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Translation Study of a Safe Teen Driving Intervention

Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease

Effects of PURPLE Cry Intervention

Lipiflow vs iLux Patient Acceptance and Comfort Study

MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients

Cardiac Safe Transplants for Systemic Sclerosis

Establishing Safe Drainage Limits for Pleural Chest Tube Removal.

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860

Evaluation of a Daily Oral Care Lozenge on Oral Health and Quality of Life in Older Adults